Ethical Guidance for Selecting Clinical Trials to Receive Limited Space in an Immunotherapy Production Facility

Abstract

Our aims are to (1) set forth a multiprinciple system for selecting among clinical trials competing for limited space in an immunotherapy production facility that supplies products under investigation by scientific investigators; (2) defend this system by appealing to justice principles; and (3) illustrate our proposal by showing how it might be implemented. Our overarching aim is to assist manufacturers of immunotherapeutic products and other potentially breakthrough experimental therapies with the ethical task of prioritizing requests from scientific investigators when production capacity is limited.

Keywords:

• human subjects research
• pharmaceutical industry
• rationing/resource allocation
• research ethics

This article is referred to by:

On Scarcity and the Value of Clinical Trials

Fairness in Manufacturing Cellular Therapies

Fairness and Desert: A Critique of the Random Selection Criterion in Clinical Trials

Ethical Ruminations of a Rheumatologist: Autoimmunity Is an Important Consideration for Immunotherapy Trials

Fairly Allocating Space in an Immunotherapy Production Facility: Reply to Critics

Perverse Effects: How Insufficient Guidance to IPFs Can Undermine Both Research and Health Outcomes of Clinical Trials

Prioritizing Facts and Values in Immunotherapy Trial Selection: Some Further Guidance

Disease Prevalence and the Magnitude of Research Benefits